Hugel, a Korean medical aesthetics company, plans to establish a direct sales organization in the United States as it aims to capture a 14 percent share of the U.S. botulinum toxin market by 2030.
Daewoong Pharmaceutical's Nabota botulinum toxin won use approval from Saudi Arabia and Ukraine, the Korean company said Wednesday.
The Supreme Court dismissed an appeal filed by the Seoul Regional Office of Food and Drug Safety in an ongoing legal row over the suspension of the sale of Hugel's botulinum toxin products, Hugel said Wednesday.
Hugel's Letybo botulinum toxin product was approved for sale in Britain, the company said Thursday.
Letybo, Hugel’s botulinum toxin product, won marketing approval from health regulators in Austria, the company said Tuesday.
Hugel’s main focus for 2022 is to go global, with the goal of claiming 10 percent of the world market share for botulinum toxin in five years.
Letybo, Hugel’s botulinum toxin product, won marketing approval from health regulators in France, the company said Thursday.
The Ministry of Food and Drug Safety will revoke the license of six botulinum toxin products manufactured by Hugel and Pharma Research Bio for violating certification and shipping regulations.
Hugel, Korea's largest botulinum toxin maker, wants 80 percent of its sales to come from overseas by 2025.
Huons BioPharma signed a deal potentially worth 97.2 billion won ($83.4 million) with Berlin, Germany’s Haemato Pharm to supply its Hutox botulinum toxin for sale in the European market.
Korea JoongAng Daily Sitemap
